[1] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021,71:209-249. [2] Diagnosis And Treatment Guidelines For Colorectal Cancer Working Group CSOCOC. Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for colorectal cancer 2018 (English version)[J].Chin J Cancer Res,2019,31:117-134. [3] Sinicrope FA, Foster NR, Thibodeau SN, et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy[J]. J Natl Cancer Inst, 2011,103:863-875. [4] Roerink SF, Sasaki N, Lee-Six H, et al. Intra-tumour diversification in colorectal cancer at the single-cell level[J]. Nature, 2018,556:457-462. [5] Domcke S, Sinha R, Levine DA, et al. Evaluating cell lines as tumour models by comparison of genomic profiles[J]. Nat Commun, 2013, 4:2126. doi: 10.1038/ncomms3126. [6] Lau HCH, Kranenburg O, Xiao H, et al. Organoid models of gastrointestinal cancers in basic and transla-tional research[J]. Nat Rev Gastroenterol Hepatol, 2020,17:203-222. [7] 国家卫生健康委员会医政司,中华医学会肿瘤学分会.中国结直肠癌诊疗规范(2023版)[J].协和医学杂志, 2023, 14:706-733. [8] De Falco V, Napolitano S, Rosello S, et al. How we treat metastatic colorectal cancer[J]. ESMO Open, 2020,4:e000813. doi: 10.1136/esmoopen-2020-000813. [9] Ji DB, Wu AW. Organoid in colorectal cancer: progress and challenges[J]. Chin Med J Engl, 2020,133:1971-1977. [10] Kopper O, de Witte CJ, Lohmussaar K, et al. An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity[J]. Nat Med, 2019,25:838-849. [11] Lohmussaar K, Oka R, Espejo Valle-Inclan J, et al. Patient-derived organoids model cervical tissue dynamics and viral oncogenesis in cervical cancer[J]. Cell Stem Cell, 2021, 28:1380-1396 e6. [12] He X, Jiang Y, Zhang L, et al. Patient-derived organoids as a platform for drug screening in metastatic colorectal cancer[J]. Front Bioeng Biotechnol, 2023,11:1190637. doi: 10.3389/fbioe.2023.1190637. [13] Ooft SN, Weeber F, Dijkstra KK, et al. Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients[J]. Sci Transl Med, 2019,11:eaay2574. doi: 10.1126/scitranslmed.aay2574. [14] Pauli C, Hopkins BD, Prandi D, et al. Personalized in vitro and in vivo cancer models to guide precision medicine[J]. Cancer Discov, 2017, 7:462-477. [15] Li L, Knutsdottir H, Hui K, et al. Human primary liver cancer organoids reveal intratumor and interpatient drug response heterogeneity[J]. JCI Insight, 2019,4:e121490. doi: 10.1172/jci.insight.121490. |